Fortress Biotech, Inc. and its subsidiary Helocyte, Inc. have initiated a Phase 2 clinical trial to assess the efficacy of the Triplex vaccine, designed to prevent cytomegalovirus (CMV) reactivation ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Federal data indicate that over half the US population aged 6-46 years is infected with cytomegalovirus (CMV), typically spread through bodily fluids. Most people have mild or no negative effects from ...

Maribavir is an effective and well-tolerated option for cytomegalovirus infection and disease among hematopoietic cell ...